PIK3CA and cancer: The pooled HR for cancer-related death considering PIK3CA-mutated tumours (Fig. 4) was calculated as 0.74 (95% CI: 0.56–0.97) with a heterogeneity of I2 = 0% (tau2 = 0, Q = 3.99, p = 0.41).